Tadalafil
- Generic Name
- Tadalafil
- Brand Names
- Adcirca, Alyq, Cialis, Entadfi, Tadliq, Talmanco (previously Tadalafil Generics), Tadalafil Mylan, Tadalafil Lilly, Adcirca (previously Tadalafil Lilly)
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19N3O4
- CAS Number
- 171596-29-5
- Unique Ingredient Identifier
- 742SXX0ICT
- Background
Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy. It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors like sildenafil, tadalafil has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment of PAH.
- Indication
Tadalafil is indicated for the treatment of erectile dysfunction (ED) and either alone or in combination with finasteride for the treatment of benign prostatic hypertrophy (BPH). It is also indicated for the treatment of pulmonary arterial hypertension (PAH) both alone and in combination with macitentan or other endothelin-1 antagonists.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Erectile Dysfunction, Pulmonary Arterial Hypertension (PAH)
- Associated Therapies
- -
Assessment of Efficacy of Vardenafil in Subjects With Erectile Dysfunction and Diabetes, Hypertension or Hyperlipidemia
- Conditions
- Interventions
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 614
- Registration Number
- NCT00668109
Evaluating the Efficacy Vardenafil 10 mg vs Tadalafil 10 mg in in Subjects With Erectile Dysfunction (ED)
- Conditions
- Interventions
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2013-10-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 759
- Registration Number
- NCT00663130
A Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Sildenafil And Tadalafil
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2021-02-01
- Target Recruit Count
- 56
- Registration Number
- NCT00644956
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, Leeds, United Kingdom
Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2013-03-22
- Target Recruit Count
- 25
- Registration Number
- NCT00626665
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
- Conditions
- Interventions
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 38
- Registration Number
- NCT00617305
- Locations
- ๐บ๐ธ
Scott & White Memorial Hospital, Temple, Texas, United States
๐บ๐ธUniversity of Iowa, Iowa City, Iowa, United States
๐บ๐ธEmory University, Atlanta, Georgia, United States
Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs
- First Posted Date
- 2007-10-25
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 357
- Registration Number
- NCT00549302
- Locations
- ๐ฌ๐ง
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
Determine Safety and Effectiveness of Tadalafil in Asian Men When Taken as Needed for Getting and Keeping an Erection
- First Posted Date
- 2007-10-22
- Last Posted Date
- 2007-10-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 367
- Registration Number
- NCT00547573
- Locations
- ๐จ๐ณ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak to your personal physician., Beijing, China
To Determine Effect and Safety of Tadalafil Taken by Men of Different Races and With Different Diseases When Needed for Erections
- First Posted Date
- 2007-10-22
- Last Posted Date
- 2007-10-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1933
- Registration Number
- NCT00547417
- Locations
- ๐บ๐ธ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems
- First Posted Date
- 2007-10-22
- Last Posted Date
- 2007-10-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 275
- Registration Number
- NCT00547625
- Locations
- ๐บ๐ธ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States
Study For Which Treatment, Tadalafil or Sildenafil, is Preferred For Problems Getting or Maintaining an Erection
- First Posted Date
- 2007-10-22
- Last Posted Date
- 2007-10-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 386
- Registration Number
- NCT00547092
- Locations
- ๐ฌ๐ง
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon- Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plymouth, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.